Form 4: CG Oncology Director Sells Shares
Insider Transaction (Form 4)
James Mulay, a Director of CG Oncology, Inc., sold 24,165 shares of common stock on July 10, 2026 for $75.16 per share.
Summary
- Option exercise/conversion: acquired 24,165 Common Stock at $26.63 ($643,514) on July 10, 2026; holds 24,165 after (Direct).
- Open-market sale: disposed of 24,165 Common Stock at $75.16 ($1,816,241) on July 10, 2026 (Direct).
- Option exercise/conversion: disposed of 24,165 Director Stock Option (right to buy) on July 10, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,816,241 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
James Mulay — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-10 | Option exercise/conversion | Common Stock | 24,165 | $27 | $643.5K | 24,165 |
| 2026-07-10 | Open-market sale | Common Stock | 24,165 | $75 | $1.8M | 0 |
| 2026-07-10 | Option exercise/conversion | Director Stock Option (right to buy) | 24,165 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-10 | Option exercise/conversion (24,165 shares) |
| 2026-07-10 | Open-market sale (24,165 shares) |
| 2026-07-10 | Option exercise/conversion (24,165 shares) |
Keywords
insider transaction, Form 4, CGON, CG Oncology, Inc., bearish, James Mulay
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.